Lonoctocog alfa API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Lonoctocog alfa API 1388129-63-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Lonoctocog alfa. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Lonoctocog alfa
- Synonyms:
- Cas Number:
- 1388129-63-2
- DrugBank number:
- DB13998
- Unique Ingredient Identifier:
- VQ723R7O8R
General Description:
Lonoctocog alfa is a chemical compound identified by the CAS number 1388129-63-2. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Half-life:
The half-life of Lonoctocog alfa is an important consideration for its dosing schedule: 8.4-19.3 hrs. This determines the duration of action and helps in formulating effective dosing regimens.
Clearance:
The clearance rate of Lonoctocog alfa is a critical factor in determining its safe and effective dosage: * 4.1 mL/h•kg. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Lonoctocog alfa exerts its therapeutic effects through: Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Lonoctocog alfa functions by: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Lonoctocog alfa is categorized under the following therapeutic classes: Hemostatics. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
